A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

NCT01006980 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

675

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: Vemurafenib
DRUG: Dacarbazine

Sponsor

Hoffmann-La Roche